
A contract research organisation based at Alderley Park has secured £700,000 in its latest funding round, led by existing investor, Mercia; the investment will help support continued growth at the firm.
Gentronix provides toxicology testing to companies developing pharmaceutical products in order to demonstrate to regulators that they are safe to use. The firm currently employs over 40 staff at its Alderley Park base and is set to employ an additional 20 staff following the investment. The contract research organisation also recently acquired the Big Blue assay, which enables the firm to expand its offering to include testing products for mutagenic properties and ensuring new drugs do not induce genetic mutations.
Matt Tate, Gentronix Managing Director, said:
“This further investment provides a fantastic platform for Gentronix to commercialise the Big Blue® technology, building on our strong reputation for high quality contract research and establishing our business as a world leading CRO in the delivery of mutagenicity safety assessments.
“The Big Blue® service is incredibly important for the continued development of safer chemicals and medicines, and we are excited to strengthen our collaborations with clients across the pharmaceutical and chemical industries by providing this. In addition, our expanded capabilities in skin and ocular toxicology services will drive business growth in new markets, allowing us to build on the growth we’ve achieved during the pandemic and creating more high quality jobs at our facilities in Alderley Park.”
Alex Gwyther of key investor Mercia, which has been involved in the firm since 2007, said:
“Gentronix’s work is crucial in helping to develop new pharmaceuticals, agrochemicals and consumer products that are safe for people and the environment. We are confident Matt and the team will go from strength to strength as they continue to serve their global clients with both their core offerings and the newly acquired Big Blue”